A: Nomesis® is used to relieve symptoms such as nausea, vomiting, motion sickness, vertigo, and morning sickness during pregnancy. It is also prescribed for patients with labyrinthine and vestibular disturbances, which affect balance and coordination. In cases of radiation sickness, Nomesis® can be used as a preventive measure when taken before treatment. The medication helps reduce dizziness and discomfort caused by these conditions, improving the patient’s overall well-being.

A: Nomesis® should be taken as prescribed by a physician. For nausea and vomiting, including morning sickness during pregnancy, the usual dose is one tablet one to two times daily. For motion sickness, one or two tablets should be taken at least one hour before travel, with the dose repeated every 24 hours if necessary. Patients suffering from vertigo are typically advised to take one tablet twice daily. In cases of labyrinthine and vestibular disturbances, the dosage varies between 25 to 100 mg daily, depending on clinical response. For radiation sickness, a 50 mg dose of Meclizine should be taken 2 to 12 hours before radiation treatment.

A: Although generally well tolerated, Nomesis® may cause some side effects in certain individuals. The most commonly reported side effects include drowsiness, dry mouth, and urinary retention. In rare cases, blurred vision may occur. These side effects are usually mild and temporary. However, patients should be cautious when engaging in activities that require alertness, such as driving or operating machinery, as the medication may cause drowsiness. If any severe or persistent side effects occur, medical attention should be sought immediately.

A: Nomesis® contains Meclizine and Pyridoxine, both of which are considered safe during pregnancy when used at recommended doses. Large-scale studies have shown no evidence of harmful effects on the fetus, and Meclizine is often the preferred medication for treating nausea and vomiting during pregnancy. Pyridoxine (Vitamin B6) is also classified as safe and is commonly used in pregnant women without adverse effects. While Meclizine may be excreted into breast milk, studies suggest that it does not pose any risk to nursing infants. However, pregnant and breastfeeding women should always consult a physician before using this medication.

A: Nomesis® is contraindicated in individuals with a known hypersensitivity to Meclizine Hydrochloride or Pyridoxine Hydrochloride. Patients with conditions such as asthma, bronchitis, emphysema, enlarged prostate, glaucoma, or urinary tract blockage should use this medication with caution, as it has potential anticholinergic effects. Additionally, patients should avoid consuming alcohol, sedatives, or tranquilizers while taking Nomesis®, as these substances may enhance drowsiness. It is also advised not to exceed the recommended dose, especially in the last two weeks of pregnancy, due to potential risks.

A: An overdose of Nomesis® may lead to symptoms such as extreme excitability, seizures, drowsiness, temporary nerve damage, or hallucinations. If an overdose is suspected, immediate medical attention should be sought. The treatment primarily involves supportive and symptomatic care. In severe cases, hospitalization may be required to monitor the patient's vital signs and manage any complications. To prevent accidental overdose, patients should always follow the prescribed dosage and store the medication in a safe place, out of reach of children.